EMERGENT BIOSOLUTIONS INC (EBS)

US29089Q1058 - Common Stock

13.97  +0.17 (+1.23%)

After market: 14.02 +0.05 (+0.36%)

Buy % Consensus

47

ChartMill assigns a Buy % Consensus number of 47% to EBS. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 8.16. This target is -41.59% below the current price.
EBS was analyzed by 9 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about EBS.
In the previous month the buy percentage consensus was at a similar level.
EBS was analyzed by 9 analysts. More opinions would make the average more meaningful.

Related screens

Price Target & Forecast

Price Low Median Mean High 13.978.088.168.168.40 - -42.16% -41.59% -41.59% -39.87%

Related screens

Up and Down Grades
Date Firm Action Rating
2024-07-03 Benchmark Reiterate Buy -> Buy
2024-07-02 Benchmark Reiterate Buy -> Buy
2024-06-24 Benchmark Reiterate Buy -> Buy
2024-06-21 Benchmark Reiterate Buy -> Buy
2024-06-20 Benchmark Maintains Buy -> Buy
2024-04-11 Benchmark Reiterate Buy -> Buy
2024-03-07 Benchmark Upgrade Hold -> Buy
2023-11-20 JP Morgan Reiterate Underweight
2023-08-29 Benchmark Downgrade Buy -> Hold
2023-05-31 Benchmark Reiterate Buy -> Buy
2023-05-19 Benchmark Reiterate Buy -> Buy
2023-04-10 Benchmark Upgrade Hold -> Buy
2023-03-17 JP Morgan Downgrade Neutral -> Underweight
2022-11-10 Benchmark Downgrade Buy -> Hold
2022-11-09 Chardan Capital Maintains Buy
2022-09-12 Cowen & Co. Maintains Market Perform
2022-05-04 Wells Fargo Maintains Equal-Weight
2022-04-29 Chardan Capital Maintains Buy
2022-03-10 Wells Fargo Maintains Equal-Weight
2021-11-10 Chardan Capital Maintains Buy
2021-11-08 Benchmark Downgrade Buy -> Hold
2021-05-05 Argus Research Downgrade Buy -> Hold
2021-04-30 Chardan Capital Maintains Buy
2021-04-07 Benchmark Initiate Buy
2021-02-24 Chardan Capital Upgrade Neutral -> Buy
2021-02-19 Chardan Capital Downgrade Buy -> Neutral